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ABSTRACT
The Effect of Omega-3 Polyunsaturated Fatty Acids Dervied from Various Sources on
Bone Metabolism in Growing Female Rats
Robin Lukas
Bone loss may be lessened if bone mass and strength are increased by optimizing nutrition
intervention. Omega-3 polyunsaturated fatty acids (ω-3 PUFAs) have been suggested to
improve bone mineralization and microarchitecture by affecting mineral balance and lipid
peroxidation. However, the sources of the ω-3 PUFA differ in the types of ω-3 PUFA, ratios,
and structural form. Therefore, the study objective was to determine the effect of ω-3 PUFAs
from different sources on bone mineral and microarchitecture and explore potential associations.
Growing (28 day) female Sprague-Dawley rats were randomly assigned (n=10/group) to a high
fat 12% (weight) diet consisting of either corn oil (CO) control or the ω-3 fatty acid rich flaxseed
(FO), krill (KO), menhaden (MO), salmon (SO), or tuna (TO). After 8-weeks of feeding, femur
and tibia were collected. Bone morphometry, bone mineralization, and microarchitecture were
measured. Bone mineralization and microarchitecture were measured by dual-energy x-ray
absorptiometry (DEXA) and micro-computed tomography (µCT), respectively. Bone strength
was measured using a 3-point bending test. Mineral balance was determined by inductively
coupled plasma optical emission spectrophotometry. Bone turnover markers were measured by
standard enzyme immunoassay (EIA). Lipid peroxidation was determined by measuring the
amount of thiobarbituric acid reactive substances (TBARS) using EIA. In the tibiae, rats fed TO
had longer (P<0.001) tibiae than rats fed CO, FO, KO, and MO. Tibiae bone mineral content
was greater in rats fed TO or SO (P<0.001) than CO-fed rats. Tibiae bone mineral density in
TO-fed rats was higher (P=0.006) compared to CO-fed rats. Trabecular microarchitecture in the
femur and tibiae showed rats fed FO or MO had improved bone microarchitecture compared to
rats fed CO or SO. There were no significant differences in bone strength. Serum osteocalcin
was higher (P=0.03) in rats fed FO compared to rats fed TO or SO. There were no significant
differences in mineral balance. Rats fed SO or TO had a lower (P<0.005) TBARS than CO, KO,
and MO, indicating that rats fed SO or TO had lower lipid peroxidation. Based on the study
results, different sources of ω-3 PUFAs influenced bone differently. Rats fed FO or MO, rich in
alpha-linolenic acid (ALA), promoted bone microarchitecture and rats fed TO, rich in
docosahexaenoic acid (DHA), had increased bone mineralization. The study results suggest that
rather than focusing on one source of ω-3 PUFAs, perhaps a variety of sources of ω-3 PUFAs
should be consumed in order to improve bone health during the growth stage of rats.
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1.0. Introduction
During childhood and adolescence, bone formation exceeds the rate of bone resorption
resulting in bone acquisition. Peak bone mass (PBM) is the maximal amount of bone mass
achieved during the growth stage (Anderson, 1996). After this stage, bone formation begins to
decline while resorption continues at the same rate, resulting in bone loss (Martini, 2006). Bone
loss occurs by demineralization and the breakdown of collagen in the bone matrix (Claassen et
al., 1995b). Bone loss leading to decreased bone strength increases the risk of osteoporosis. In
the absence of a cure for osteoporosis, emphasis is placed on the prevention of bone loss.
Studies suggest that the onset of osteoporosis may be delayed and severity of osteoporosis may
be lessened if bone modeling during the growth stage is optimized to achieve maximal PBM
(Hansen, 1991; Matkovic, 1994). The lack of effective treatments for osteoporosis results in
emphasis on prevention, such as dietary strategies to improve bone health during the growth
stage. Dietary intervention to achieve maximal PBM and to prevent bone loss has focused on
calcium (Ca) and factors influencing Ca balance.
Studies have reported that dietary fatty acid intake affect Ca balance (Cashman 2007,
Claassen et al., 1995a; Hogstrom et al., 2007; Kruger et al., 1997; Kruger et al., 2005; Poulsen et
al., 2007; Salari et al., 2008; Watkins et al., 2003; Weiss et al., 2005). Rats receiving a Ca
adequate diet and provided fish oil supplements increased Ca transport across the basolateral
membrane and decreased fecal Ca excretion (Claassen et al., 1995). EPA and DHA have been
reported to increase Ca2+ ATPase activity, a membrane protein that transports Ca, that promotes
Ca absorption and thereby, overall Ca balance. Omega-3 polyunsaturated fatty acids (ω-3
PUFAs) also affect various factors influencing osteoclasts and osteoblasts. The essential fatty
acid linoleic acid (LA, 18:2 ω-6) can be metabolized to prostaglandin E2 (PGE2). PGE2
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stimulates bone formation at low concentrations, but inhibits at high concentrations (Mollard et
al., 2005). High concentrations of PGE2 also increased various cytokines observed to be active
in the pathogenesis of osteoporosis (Salari et al., 2008).
The ω-3 PUFAs compete with ω-6 PUFAs for the same enzymes and therefore, may
inhibit PGE2 synthesis (Schwalfenberg 2006). The ω-3 PUFAs, alpha-linolenic acid (ALA, 18:3
ω-3), docosahexaenoic acid (DHA, 22:6 ω-3), and eicosapentaenoic acid (EPA, 20:5 ω-3) have
been reported to reduce osteoclast activity, suppress bone resorption, and to increase bone
mineral density (BMD) (Hogstrom et al., 2007; Griel, 2007; Weiler et al., 2002; Weiss et al.,
2005). Various sources of ω-3 PUFA are commercially available as dietary supplements.
However, sources of ω-3 PUFA may differ in fatty acid type, EPA:DHA ratio, and/or structural
form. Therefore, the objective of this study was to determine the effect of feeding growing
female rats different sources of ω-3 PUFAs on bone mineralization, microarchitecture, and
strength. To our knowledge, this is the first study to compare the effect of different sources of
ω-3 PUFAs on bone health.
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2.0. Study Hypothesis and Objectives
Different sources of ω-3 PUFAs, due to their differing types of fatty acids, ratios of EPA and
DHA and their structural form, will vary in their ability to affect mineral balance, bone mass,
bone mineral content, and bone mineral density when consumed by young growing rats.

In order to test the hypothesis the study objectives were:
1. To determine the effects of feeding growing female rats ω-3 PUFAs from different
sources on bone morphometry, bone mass, microarchitecture, and bone strength.
2. To determine potential mechanisms of ω-3 PUFAs from different sources on bone health
in growing female rats.
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3.0. Literature Review
3.1. Bone Biology
The skeletal system functions to support the body structurally, store minerals and lipids,
produce blood cells, protect soft tissues, and act as levers to change direction and magnitude of
the forces from skeletal muscles. Several segments make up the long bone (Figure 1). The
diaphysis is the bone’s shaft and the epiphyses are the proximal and distal ends of the bone
(Martini, 2006). In a mature bone, the metaphyses are where the diaphysis joins the epiphyses.
In a growing bone, the metaphyses include the epiphyseal plate. A tough sheath of dense
irregular connective tissue called the periosteum covers the bone. Cartilage covers the bone
where the bone forms a joint with another. The marrow cavity (i.e., medullary cavity) is the
space within the diaphysis that contains bone marrow. The microarchitecture of the bone
consists of epiphyses containing spongy or trabecular bone. Trabecular bone has a honeycombed
structure and has a thin covering of cortical bone (Martini, 2006).

Figure 1: Structure of a bone (British Broadcasting Corporation <http://www.bbc.co.uk>)
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In cortical bone, calcium phosphate [Ca3(PO4)2] accounts for almost two-thirds of the
weight of the bone (Martini, 2006). Calcium phosphate interacts with calcium hydroxide,
[Ca(OH)2] to form crystals of hydroxyapatite, [Ca10(PO4)6(OH)2]. Formation of hydroxyapatite
crystals includes incorporation of other Ca salts and ions such as sodium, magnesium, and
fluoride. The hard and brittle hydroxyapatite crystals are stored in the bone matrix and can
withstand compression, but break when bent or twisted (Martini, 2006). In contrast, collagen
fibers in the bone matrix are flexible and can tolerate twisting or bending, but not compression
(Martini, 2006). The combination of the hydroxyapatite crystals and collagen fibers forms a
strong bone that is somewhat flexible and highly resistant to fracture.
Demineralization and the breakdown of collagen in the bone matrix results in bone loss
(Claassen et al., 1995b). Cortical mineralization can be determined by using dual energy x-ray
absorptiometry (DEXA) to measure bone mineral density (BMD), bone mineral content (BMC)
and bone mineral area (BMA). BMD represents a measurement of the bone mass per cm2, BMC
represents the mass of the bone, and BMA represents the area of bone occupied by minerals.
Decreased BMD and BMC increase bone fragility and susceptibility to fracture (Cashman,
2007).
Bone architecture can be determined using micro-computed tomography (µCT).
Trabecular bone volume to total tissue volume ratio (BV/TV) is the trabecular fraction of bone in
the sample, trabecular number (TbN) is the number of trabeculae per mm of bone, trabecular
thickness (TbTh) represents the mean diameter of the trabeculae, trabecular separation (TbSp) is
the mean size of the intertrabecular spaces, connectivity density (CONN) is a quantified
measurement of elasticity, and structure model index (SMI) characterizes the type of structure of
the sample (rod-like, plate-like, or mixed structures). High values for BV/TV, TbN, TbTh and
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CONN correlate with a strong bone. High values for TbSp indicate a weak bone. A bone having
more rod-like structures is weaker than bone having more plate-like structures (Parkinson et al.,
2009). For an ideal plate structure, SMI is close to 0 and for an ideal rod structure the value is 3.

3.2. Osteoporosis
As shown in Figure 2, loss of bone mineral and matrix (i.e. microarchitecture) is the
major factor underlying osteoporotic fracture (Cashman, 2007).

Figure 2: Scanning electron micrograph of a normal bone (Panel A) and a bone with osteoporosis (Panel B)
<pdrhealth.com>

Fractures due to osteoporosis lower a patient’s quality of life. According to the National
Osteoporosis Foundation (2009), 1 in 5 individuals who were ambulatory before their hip
fracture required long-term care afterward. Hip or vertebral fractures are also linked to an
increased risk of death. An average of 24 percent of hip fracture patients, aged 50 and over, die
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within a year following fracture. In the absence of a cure for bone loss leading to osteoporosis,
maximizing PBM during growth by promoting bone formation is a major strategy for reducing
the future risk of osteoporosis.

3.3. Bone Turnover and Growth
Cells account for 2% of the mass of a typical bone. There are 4 types of cells in the bone:
osteocytes, osteoblasts, osteoprogenitor cells, and osteoclasts. Osteocytes maintain the protein
and mineral content of the surrounding matrix and repair the bone when damaged (Martini,
2006). Osteoblasts produce new bone matrix, facilitate bone mineralization, and assist in
increasing local concentrations of calcium phosphate and promoting the deposition of Ca salts in
the bone matrix (Martini, 2006; Watkins et al., 2001a). Osteoprogenitor cells are stem cells that
divide to produce daughter cells that differentiate into osteoblasts (Martini, 2006). These cells
maintain osteoblast population and are important in the repair of a fracture. Osteoclasts are
special macrophage-like cells (Poulsen, 2007) that remove bone matrix (Martini, 2006) in a
process called resorption. Resorption is important in the regulation of blood Ca and P
concentrations. Ca and P are mobilized from bone stores when blood Ca and P concentrations
are low.
The process of resorption and formation of new bone known as bone turnover is
continuous. Bone turnover begins with the recruitment of osteoclasts from bone marrow
precursors (Watts, 1999). Osteoclasts secrete proteolytic enzymes and acids to dissolve the
matrix and release the stored minerals (Martini, 2006). After removal of old bone, osteoblasts
differentiate from connective-tissue precursors and release proteins to form new bone matrix.
Bone formation is coupled to bone resorption, but do not always occur at the same rate. Growth
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of the bone occurs when bone formation exceeds bone resorption. In rats, bone continues to
grow until age 6 months after which bone growth slows (Martin, 2003). In humans, after the age
of 35-40, bone resorption exceeds bone formation resulting in a net loss of bone (Watts, 1999).

3.4. Bone Turnover Markers
There are three categories of bone turnover markers: enzymes/proteins that are secreted
by cells involved in remodeling process, breakdown products generated in the resorption of old
bone, and byproducts produced during the synthesis of new bone (Watts, 1999). A collagen
breakdown product commonly used as an indicator of osteoclast activity (i.e. bone resorption) is
pyridinoline (PYD) cross-links. A high level of serum PYD indicates that bone resorption is
occurring within the bone.
Serum osteocalcin is commonly used as an indicator of bone formation (osteoblast
activity). Osteocalcin is a bone-specific protein released into the blood during new matrix
formation (Poulsen et al., 2007). Osteoblasts are rich in alkaline phosphatase, however the
function of this enzyme is unknown (Watts, 1999). Osteoblast as well as osteoclast activity
regulate bone mass (Poulsen et al., 2007). Bones weaken when osteoclasts remove bone faster
than osteoblasts deposit bone (Martini, 2006). A low bone mass result in decreased bone
strength, and decreased bone strength (bone fragility) is defined as susceptibility to fracture
(Turner, 2002).
One issue with turnover markers is that it only provides information at a single time
point. To prevent this, multiple measurements must be made over a time period in order to
understand the true value of the marker. However, the amount of blood required to do multiple
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testing is greater than the amount found in a rat. For that reason, rat studies usually only do a
single time point measurement of turnover markers.

3.5. Bone Biomechanics
Bone fragility is defined by biomechanical parameters. These parameters include:
strength, brittleness, work to failure, and stiffness (Turner, 2002). Shown in Figure 3 is a forcedisplacement curve generated by strength testing used to calculate bone biomechanical
parameters.

Figure 3: Force-displacement curve resulting from a biomechanical test of
a bone specimen. Adapted from Turner 2002.

Peak force is defined as the highest point of the curve. Ultimate stiffness is the slope of
the curve. Bending energy failure is defined as the area under the curve and brittleness is
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estimated from the reciprocal of the curve (Turner, 2002). Ultimate bending stress is a
normalized calculated force that takes into account the size of the bone and Young’s Modulus is
normalized stiffness that also takes into account bone size (Yuan et al., 1992).

3.6. Peak Bone Mass
PBM is defined as the highest level of bone mass achieved during the growth stage (Hind
et al., 2007). PBM is achieved a few years after the fusion of the epiphyses (Heaney, 2000). It is
important to maximize PBM during the growth stage because during this stage, increased bone
formation results in increased bone accrual, size, and bone strength (Hind et al., 2007). After
this stage, around age 35 to 40 years old in humans, bone resorption exceeds bone formation
resulting in steady bone loss. Females are at increased risk of osteoporosis due to their lower
PBM compared to males (Nieves, 2005). Therefore, female rats were used in this study. Low
PBM is a recognized “risk factor” for osteoporosis later in life (Hawker et al., 2002). To prevent
future risk of osteoporosis it is important to identify modifiable factors that may improve PBM
during this critical stage of bone acquisition. Nutrition is an important modifiable factor that
may influence PBM. Recently, there has been increasing evidence that dietary fatty acids and
their eicosanoid derivatives affect bone metabolism. The next section reviews	
  ω-3 PUFAs and
their role in bone health.

3.7. Omega-3 Polyunsaturated Fatty Acids
An essential nutrient is one that must be obtained from the diet because the body cannot
produce it in adequate amounts. The essential fatty acid linoleic acid (LA, 18:2 ω-6), when
consumed in sufficient quantities may be converted to the long-chain PUFA, arachidonic acid
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(AA, 20:4 ω-6) by endogenous desaturase and elongase enzymes. Eicosanoids can be
synthesized from AA by the cyclooxygenase (COX) enzymes (Figure 4). Eicosanoids are
biologically active compounds that are involved in modulating the intensity and duration of
inflammatory responses (Calder, 2002). AA produces the n-2 series prostaglandin (PG), one of
which is PGE2. PGE2 regulates inflammatory cytokines such as: TNF-α, IL-1, and IL-6.
Therefore, overproduction of AA-derived eicosanoids may place the body in a pro-inflammatory
state (Calder, 2002; Watkins et al., 2001a). The dramatic rise in LA intake over the last 50 years
from the widespread use of vegetable oil such as corn oil, may lead to a pro-inflammatory state
(Fritsche, 2008). An acute inflammatory response is useful, for it isolates the damaged area,
mobilize effector cells to the site of injury, and promote healing (Kimball, 2010)
The ω-3 essential fatty acid, alpha-linolenic acid (ALA, 18:3 ω-3) when consumed in
sufficient quantities may be converted to long chain PUFA, eicosapentaenoic acid (EPA, 20:5 ω3). EPA may then be converted to docosahexaenoic acid (DHA, 22:6 ω-3). ALA is converted to
EPA using the same desaturase and elongase enzymes used to convert LA to AA. Therefore, LA
and ALA may competitively inhibit one another. Competitive inhibition of LA by ALA reduces
AA. This in turn, may result in a reduction of pro-inflammatory PGE2.
Marine oils provide a rich source of the long-chain ω-3 PUFAs, EPA and DHA. This is
of health significance because EPA competes with AA for the COX enzyme regulating
eicosanoid synthesis (Shane et al., 2002). Competitive inhibition of AA by EPA also reduces n-2
series pro-inflammatory eicosanoids and increases synthesis of the less inflammatory n-3 series
eicosanoids (Figure 4). The richest source of ALA is flaxseed (Cunnane, 1995). However
conversion of ALA to EPA (0.2%) and DHA (0.5%) is inefficient (Ratnayake et al., 2009).
Therefore, consuming foods rich in EPA and DHA is recommended by the American Heart
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Association, American Dietetics Association, and Council for Responsible Nutrition (Ismail,
2010). Consumption of EPA and DHA from fish or fish oil has been shown to partially replace
the ω-3 PUFA that are in the phospholipid bilayer in white blood cell (Salari et al., 2008;
Simopoulos, 1991).

Figure 4: Polyunsaturated fatty acid metabolism

Marine oils provide a rich source of the long-chain ω-3 PUFAs, EPA and DHA. A
popular commercial fish oil supplement is menhaden oil. Salmon and tuna are commonly eaten
fish in the Western diet. Krill is another seafood source of ω-3 PUFAs. In krill oil, fatty acids
are associated mainly with phospholipids; whereas, fatty acids in fish oil are associated with
triglycerides (Bottino, 1975; Gigliotti et al., 2010). Phospholipids have been suggested to be
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better absorbed than triglycerides (Amate et al., 2001). Therefore, in this study, flaxseed oil,
krill oil, and three fish oils (salmon, tuna, and menhaden) were the different sources of ω-3
PUFAs used.
It has been suggested by the American Heart Association that ω-3 PUFA consumption
should be increased. Currently, the ratio of ω-6:ω-3 is at ~10:1 in a typical Western diet (KrisEtherton et al., 2003). However, Simopoulous (2008) has suggested that the ω-6:ω-3 ratio
should be closer to 2:1. Cell membrane changes due to the ratio of ω-6:ω-3 PUFA may lead to
changes in tissue function, such as production of cytokines (Simopoulos, 2002). Calder (2002)
suggested that increasing ω-3 PUFAs in membranes might decrease inflammation by reducing
the production of pro-inflammatory eicosanoids (i.e. PGE2) and cytokines (i.e. TNF-α). PGE2 is
involved in inflammation for it induces fever, increase vascular permeability and vasodilatation,
and enhancing pain and edema (Calder, 2002). It also suppresses lymphocyte proliferation and
inhibits production of IL-2, thus, in these respects PGE2 is immunosuppressive (Calder, 2002). It
is important to note that an excess of ω-3 PUFAs will decrease coagulation in the blood, which
could result in hemorrhaging. Therefore, it is important to establish safe levels of ω-3 PUFAs.
The next section reviews the effect of ω-3 PUFA in bone tissue.

3.8. Omega-3 Polyunsaturated Fatty Acids and Bone Health
While is has been well established that ω-3 PUFAs are heart healthy, its effects on bone
are not as well known. Claassen et al. (1995b) investigated whether the ω-3 PUFA EPA,
provided as fish oil, and ω-6 PUFAs gamma-LA (γ –LA) provided as primrose oil, influenced
bone status in growing (age 21 days) male Sprague-Dawley rats. Rats were fed a diet
supplemented with different ratios of ω-3 PUFA (as fish oil) and ω-6 PUFA (as evening
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primrose oil) for 3 months. Rats fed diets of 1:3 γ-LA:EPA had reduced bone matrix collagen
degradation (P<0.05) compared to the control rats fed 3:1 of LA:ALA as measured by bone
resorption biomarkers. Results suggested a higher ω-3 PUFA ratio may be beneficial to bone. In
a human study of adolescent white males (average age 16.7 years), a higher ratio ω-6:ω-3 PUFA
intake showed a negative correlation to spine BMD (r=-0.26, P=0.02); whereas, serum DHA and
ω-3 PUFA concentrations were positively correlated to spine (r=0.30, P=0.008) and total body
(r=0.32, P=0.004) BMD (Hogstrom, 2007). The results suggested consumption of ω-3 PUFA,
especially DHA, increased bone mineralization during growth.
Dietary fatty acids affect the bone by various mechanism of action. In a human study,
Griel et al. (2007) fed 20 male and 3 female subjects (average age of 49 years) plant-derived ω-3
PUFAs. The diets consisted of a typical American diet (control, 9:1 ω-6:ω-3) or high ω-3 diets
consisting of ratios 3.5:1 and 1.6:1. Total fat content was ~35% of energy. Sources of the oil
came from walnut and flaxseed oil, which are rich in the ω-3 PUFA, ALA. Subjects fed high
ω-3 PUFAs compared to the typical American diet high in ω-6 fatty acids, had reduced
osteoclast activity indicated by reduced serum N-telopeptide concentrations and maintained
osteoblast activity indicated by no change in bone-specific alkaline phosphatase. The results
showed the high ω-3 PUFA diet prevented bone loss by decreasing bone resorption while
maintaining bone formation. However, the study results did not distinguish whether the effects
were due to ALA or the conversion of ALA to EPA.
Indirectly, dietary fats may affect bone by altering Ca balance. Kruger et al. (2005)
reported young (age 5 weeks) male Sprague-Dawley rats fed 5% tuna oil g/kg diet had
significantly higher Ca absorption and decreased urinary Ca compared to the rats fed evening
primrose oil. The authors suggested that cell membrane saturation reduced Ca absorption and
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decreased cell membrane saturation due to ω-3 PUFA consumption resulting in increased Ca
absorption and decreased urinary Ca loss. Further, the authors suggested that in addition to
absorption and excretion, essential fatty acids LA or ALA may affect Ca retention. Claassen et
al. (1995a) fed growing (age 21 days) male Sprague-Dawley rats different ratios of γ-LA:EPA.
Ratio of 3:1 of γ-LA:EPA decreased Ca excretion and led to rats with higher (P<0.05) bone Ca
content compared to the control ratio of 3:1 of LA:ALA.
Another potential mechanism whereby ω-3 PUFAs may influence bone is by altering the
synthesis of PG. Watkins et al. (2000) compared the effect of different dietary ratios of ω-6:ω-3
PUFA on PGE2 production and bone. Weanling (age 21 d) male Harlan Sprague-Dawley rats
were fed a standard purified 7% soybean oil g/kg diet in American Institute of Nutrition 93G diet
(AIN-93G, Harlan Teklad, WI) (control diet), or AIN-93G with 7% test oil g/kg diet containing
different proportions (ω-6:ω-3 ratio of 9:1, 4:1, 1:1, and 1:2.3; wt/wt) of safflower oil, a rich
source of ω -6 PUFAs, and menhaden oil, a rich source of ω-3 PUFAs, EPA and DHA. Rats fed
higher amounts of menhaden oil for 42 days had lower production of PGE2 in the liver
(P=0.0002), tibia (P=0.02) and femur (P=0.006). Serum bone-specific alkaline phosphatase, an
indicator of osteoblast activity, was also higher (P=0.04) in rats consuming a greater amount of
ω-3 PUFA. Regression analysis showed a negative correlation between high ω-6: ω-3 ratio and
bone formation as indicated by bone-specific alkaline phosphatase (r2=0.34, P=0.01). Also, a
negative correlation was shown between PGE2 and bone formation (r2=0.22, P=0.05). The
results indicated increasing ω-3 PUFA intake promoted bone formation by increasing osteoblast
activity by bone-specific alkaline phosphatase and reducing the PGE2 associated with high ω-6
PUFA consumption.
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Another possible mechanism of action of ω-3 PUFAs on bone is the potential of PG to
alter cytokine production. Inflammatory cytokines such as TNF-α	
  are known to regulate
osteoblastic cells (Walsh et al., 2006). TNF-α inhibits the differentiation of osteoblasts and
inhibits collagen synthesis by osteoblasts (Walsh et al., 2006). Ferrucci et al. (2006) reported a
diet high in ω-3 PUFA lowered AA derived cytokines such as IL-6, TNF-α, and C-reactive
protein. In summary, dietary fats potentially affect the bone by various mechanisms that include
alteration in Ca absorption and urinary Ca loss, PG synthesis, and cytokine synthesis (Salari et
al., 2008).
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4.0. Materials and Methods
4.1. Animals and Diets
The Institutional Animal Care and Use committee at West Virginia University approved
the protocol for this study. All animal procedures used in this study conformed to the National
Research Council (NRC) Guide for the Care and Use of Laboratory Animals. Growing (age 28
days) female Sprague-Dawley rats (n=60) were obtained from Hilltop Laboratory (Scottdale,
PA). Rats were individually housed in metabolic cages under conditions of controlled
temperature (22 ± 20C) and a 12-h light:dark cycle. During the 7-day acclimation, all animals
were given ad libitum access to deionized distilled water (ddH2O) and the American Institute of
Nutrition 93G diet (AIN-93G, Harlan Teklad, WI). The AIN-93G was fed because it is a
purified diet that provides precise levels of minerals, and meets the National Research Council
(1995) nutrient recommendation for growing rats.
After 7 days acclimation, the rats were randomly assigned (n=10 rats/group) to a high fat
(12% by weight lipid diet, ~27% by kcal) diet consisting of: 1) corn oil (CO), 2) flaxseed oil
(FO), 3) krill oil (KO), 4) menhaden oil (MO), 5) salmon oil (SO), or 6) tuna oil (TO). CO was
added to MO and KO in order to meet the NRC recommendation for the essential ω-6 PUFA,
LA. Treatment diet was formulated based on the AIN-93G formulation using 12% instead of 7%
lipid g/kg diet. A high fat diet was used to imitate the typical Western human diet. All diets
were adjusted to have a similar fat content, to be isocaloric, and to contain 357 mg/kg diet of
calcium carbonate and 196 mg/kg diet of potassium phosphate. Diet composition is shown in
Table 1. Fatty acid composition of dietary oils is shown in Table 2. CO was chosen for its
prevalence in the typical Western diet and for its high ω-6:ω-3 ratio. FO was chosen because it
is high in the ω-3 PUFA, ALA and does not contain EPA or DHA. KO was chosen since its
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fatty acids are mainly in phospholipid form instead of triglyceride form (Gigliotti et al., 2010).
KO and MO have the same EPA:DHA ratio, however MO is in the triglyceride form. MO was
chosen because it is a common source used in studies. SO and TO are common sources of fish
oil supplements and are commonly eaten fish. TO has a lower EPA:DHA ratio than SO. CO,
FO, MO, SO, and TO were kindly provided by J. Edwards International Inc. (Quincy, MA). KO
was obtained from Enzymotec Ltd. (Morristown, NJ). Oils were analyzed for fatty acid content
by gas chromatography. Lipid classes were separated and quantified by thin layer
chromatography (TLC) according to Gigliotti et al. (2011). Rats were fed 14.75 ± 0.75 g
diet/day of their assigned diet and provided ad libitum access to ddH2O throughout the 8 week
feeding study. Food intake and spillage was recorded and fresh diet was provided daily. Water
consumption and body weights were measured weekly.
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Table 1: Ingredient Composition of the Treatment Diets
Ingredients (g/kg diet)

CO

FO

KO

MO

SO

TO

Test oil

0.0

120.0

118.0

118.0

120.0

120.0

Corn oil

120.0

0.0

2.0

2.0

0.0

0.0

Casein

200.0

200.0

200.0

200.0

200.0

200.0

L-cysteine

3.0

3.0

3.0

3.0

3.0

3.0

Corn starch

347.5

347.5

347.5

347.5

347.5

347.5

Maltodextrin

132.0

132.0

132.0

132.0

132.0

132.0

Sucrose

100.0

100.0

100.0

100.0

100.0

100.0

Cellulose

50.0

50.0

50.0

50.0

50.0

50.0

Vitamin mix

10.0

10.0

10.0

10.0

10.0

10.0

Choline bitartrate

2.5

2.5

2.5

2.5

2.5

2.5

Mineral mix1

35.0

35.0

35.0

35.0

35.0

35.0

Calcium Carbonate

0.357

0.357

0.357

0.357

0.357

0.357

Potassium Phosphate

0.196

0.196

0.196

0.196

0.196

0.196

(monobasic)

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
1

Ingredients of the AIN-93G Mineral Mix (g/kg): Calcium Carbonate = 357, Potassium Phosphate = 196, Potassium
Citrate = 70.78, Sodium Chloride = 74, Potassium Sulfate = 46.6, Magnesium Oxide = 24.3, Ferric Citrate = 6.06,
Zinc Carbonate = 1.65, Manganous Carbonate = 0.63, Cupric Carbonate =0.31, Potassium Iodate = 0.01, Sodium
Selenate = 0.0103, Ammonium Paramolybdate = 0.008, Sodium Meta-Silicate = 1.45, Chromium Potassium Sulfite
= 0.275, Lithium Chloride = 0.0174, Boric Acid = 0.0815, Sodium Fluoride = 0.0635, Nickel Carbonate Hydroxide
= 0.0318, Ammonium Meta-Vanadate = 0.0066, Sucrose = 220.716. Abbreviations are: CO=corn oil, FO=flaxseed
oil, KO=krill oil, MO=menhaden oil, SO=salmon oil, TO=tuna oil.
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Table 2: The ω-6 and ω-3 Polyunsaturated Fatty Acid Composition of Dietary Oils2
Fatty Acid1
CO
FO
KO

MO

SO

TO

ω-6 PUFAs
Linoleic acid (LA, 18:2 ω-6)

57.8

15.5

1.9

0.7

4.0

1.7

Arachidonic acid (AA, 20:4 ω-6)

0

0

0

0

0

1.9

Alpha-linolenic acid (ALA, 18:3 ω-3)

1.0

55.9

1.3

3.1

1.4

0.7

Eicosapentaenoic acid (EPA, 20:5 ω-3)

0

0

20.3

9.0

14.4

8.6

Docosahexaenoic acid (DHA, 22:6 ω-3)

0

0

5.9

3.3

3.5

24.8

EPA:DHA

n/a

n/a

3:1

3:1

4:1

1:3

ω -6: ω -3

60:1

1:4

1:14

1:23

1:5

1:9

ω-3 PUFAs

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
2	
  Results are given as percent of total fatty acid. Abbreviations are CO=corn oil, FO=flaxseed oil, KO=krill oil, MO=menhaden oil,
SO=salmon oil, TO=tuna oil, PUFA=polyunsaturated fatty acids	
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4.2. Bone Morphometry
At the end of the 8-week feeding study, the rats were food-deprived overnight. Rats were
euthanized by carbon dioxide inhalation. Both the left and right femurs and tibiae bones were
collected by disarticulating the hip joint. The long bones were cleaned of all soft tissue. Each
bone was wrapped in ddH2O-soaked gauze and stored at -200C until analyzed.
For analysis, each bone was brought to room temperature. Morphometry measurements
of bone length, width, and depth were measured using a vernier caliper (Bel-Art Products,
Pequannock, NJ). Length was measured from medial condyle to greater trochanter. Diameter
was measured at mid-section of shaft from lateral to medial end (i.e. diaphysis). Bones were
dried at 1100C for 48 h then were weighed using an analytical balance (A-200DS, Fisher
Scientific).

4.3. Bone Mineral, Calcium, and Phosphorus Content
The left long bones were packed on dry ice and shipped overnight to Dr. Brenda Smith at
Oklahoma State University to determine BMA, BMC, and BMD of the whole tibia and femur by
dual-energy x-ray absorptiometry (DEXA) (Hologic QDR 4500-A Elite). BMA, BMC, and
BMD scans were evaluated using the Regional High Resolution software package (Hologic
Waltham, MA). To determine total bone ash, femurs and tibiae were dried for 48 h at 1100C
then placed in a muffle furnace (model CP18210, Thermolyne, Dubuque, IA) at 6000C for 24 h.
Total ash was determined by weighing the bone ash. To determine Ca and P, ashed bones were
crushed and acidified in 2 mL of 6M nitric acid. The acidified samples were neutralized in 5 ml
ddH2O and filtered through Whatman no. 1 paper. Samples were diluted to a final concentration
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of 1:500 ddH2O. Ca and P concentrations in samples were determined by inductively coupled
plasma optical emission spectrophotometry (ICP, model P400, Perkin Elmer, Shelton, CN).

4.4. Bone Microarchitecture
Trabecular and cortical bone architecture were determined in the left bones using microcomputer tomography (µCT) (MicroCT40, SCANCO Medical, Switzerland). The distal femur
metaphysis and proximal tibial metaphysis were scanned and 200 images (~16 µm/slice or 3.2
mm) were analyzed by semi-automatically placing contours beginning 25 slices (400 µm) away
from the growth plate and includes only secondary spongiosa within the volume of interest
(VOI). Cortical bone architecture of the femur and tibia mid-diaphysis were evaluated on 32
slices (512 µm). Cortical indices included the medullary area and cortical thickness, area, and
porosity. All scans were performed utilizing a 1024 x 1024 matrix resulting in an isotropic voxel
resolution of 22 µm3. An integration time of 70 milliseconds per projection was used with a
rotational step of 0.36 degrees resulting in total acquisition time of approximately 150
minutes/sample. The VOI was assessed for structural parameters including trabecular bone
volume per unit of total volume (BV/TV), trabecular number (TbN), trabecular thickness
(TbTh), trabecular separation (TbSp), structure model index (SMI), and connectivity density
(CONN).

4.5. Bone Biomechanics
Bone strength indices were determined using a TA.XT2i Texture Analyzer (Texture
Technologies, Scarsdale, NY) outfitted with a three-point bending apparatus. Femora and tibiae
were placed on supports. Span between the supports was 1 cm for both the femora and tibia.
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The bone was bent until broken by lowering a centrally placed blade (1 mm width) at a constant
crosshead speed (0.1 mm/sec) and load cell of 250kg. A force-deformation curve (Figure 3) was
used to determine mechanical properties.

Peak force (N): the maximum force obtained during the bending procedure resulting in the
initiation of the bone breaking.

Ultimate stiffness (N/s): the slope of the time-force deformation curve.

Ultimate bending stress (UBS, N/mm2): a calculation of force that takes into consideration the
size of the bone calculated as:
UBS =

8 × peak force ×L × a1
_____________________
Л ((a13a2)-(b13b2))

Where L is the distance between the supporting points; a1= the outer diameter in the direction of
the load, a2= the outer diameter at right angles to a1, b1=the inner diameter in the load direction
and b2=the inner diameter at right angles to b1.

Young’s Modulus (N/mm2): a calculation of stiffness that takes into consideration the size of the
bone calculated as:
Young’s Modulus =

4× L3× ultimate stiffness (slope)
____________________________
3× Л ((a13a2)-(b13b2))
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Where L=the distance between the two edges in the three-point bending, a1= the outer diameter
in the direction of the load, a2 = the outer diameter at right angles to a1, b1=the inner diameter in
the load direction and b2 = the inner diameter at right angles to b1.

Bending Energy Failure (N.s): the area under the time-force deformation curve.

4.6. Mineral Balance
Ca and P balance was determined according to Tsanzi et al. (2008). Briefly, rats were
housed individually in metabolic cages to determine food and water intake and to collect feces
and urine. Treatment diets’ Ca and P intake were determined by ICP (model P400) and Ca and P
intake calculated by multiplying by their food intake. Ca intake was calculated as food intake (g)
x 0.5% Ca. P intake was calculated by food intake (g) x 0.3% P.
Feces and urine were collected at baseline and during the final week of the 8-week
feeding study. Ascorbic acid (0.1%) was added to the urine collection tubes as a preservative
and 1 mL mineral oil to prevent evaporation. Collected urine samples were centrifuged at 1,500
g for 10 minutes at 40C. Following centrifugation, urine samples were aliquoted into fresh tubes
and kept at -200C until assayed. Urinary concentration of creatinine was measured using a
commercially available enzyme immunoassay (EIA) kit (Quidel Corp, CA). Urine samples were
corrected for urinary volume. No significant differences were found in the creatinine values
among the treatment groups; therefore, it was unnecessary to correct the urinary Ca values by
dividing by the creatinine values.
Collected fecal samples (200 mg/rat) were freeze-dried for 48 h and then ashed in a
muffle furnace at 6000C for 18-24 h. Ashed fecal samples were acidified with 2 mL of 6M nitric
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acid. The acidified samples were neutralized in 5 ml ddH2O and filtered through Whatman no. 1
paper and diluted to a final concentration of 1:50. Fecal and urinary Ca and P concentrations
were determined by ICP (model P400).
Ca apparent absorption was calculated as [(Ca intake – fecal Ca excretion)/Ca intake] x
100. Calcium retention was determined by calculating [Total Ca intake – (fecal Ca excretion +
urinary Ca excretion)]. P absorption and retention was calculated using the same formulas.

4.7. Bone Turnover Markers
Serum was obtained at time after euthanasia and then centrifuging trunk blood samples at
1,500 g for 10 minutes at 40C. Serum samples were stored at -800C until assayed. Serum
osteocalcin and alkaline phosphatase were measured as indicators of osteoblast activity (bone
formation). Serum alkaline phosphatase was determined by veterinary test rotor colorimetric
assay (Vet-16) and measured using a Hemagen Analyst automated spectrophotometer (Hemagen
Diagnostics Inc, Columbia, MD). Serum osteocalcin was determined as an indicator of
osteoblastic activity using a commercially available rat specific enzyme-linked immunosorbent
assay (ELISA) (Biomedical Technologies, Stoughton, MA). Serum PYD was determined as an
indicator of osteoclast activity using a commercially available ELISA kit (Quidel Corporation,
CA). Optical density was measured at 450 nm using a Spectramaz Plus microplate reader
(Molecular Devices, Sunnyvale, CA).

4.8. Biochemical Measurements
Serum Ca and P were determined by Vet-16 rotor colorimetric assay and measured using
a Hemagen Analyst automated spectrophotometer (Hemagen Diagnostics Inc, Columbia, MD).
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To measure the short lived molecule, PGE2, in the urine, its metabolite 13, 14-dihydro-15-keto
PGE2 was determined using a commercially available EIA assay kit (Cayman Chemicals, Ann
Arbor, MI). Serum TNF-α was determined using a commercially available EIA assay kit
(Cayman Chemicals, Ann Arbor, MI). Absorbance for both PGE2 and TNF-α was read at 405
nm using a Spectramax Plus microplate reader (Molecular Devices, CA).
To determine lipid peroxidation, thiobarbituric acid reactive substances (TBARS) were
measured using a commercially available colorimetric EIA kit (Cayman Chemical, Ann Arbor,
MI). Absorbance was read at 540 nm using a Spectramax Plus microplate reader (Molecular
Devices, CA). Total antioxidant capacity was measured using a commercially available
antioxidant assay colorimetric EIA kit (Cayman Chemical, Ann Arbor, MI). Absorbance was
read at 750 nm using a Spectramax Plus microplate reader (Molecular Devices, CA).

4.9. Statistical Analysis
Results are expressed as means ± standard error of the mean (SEM). A one-way analysis
of variance (ANOVA) was used to determine differences among the treatment groups. Post-hoc
multiple comparison tests were performed using Tukey's test (parametric) with treatment
differences considered significant at P<0.05. Kruskal-Wallis on Ranks (non-parametric) was
used. All statistical analyses were done using the statistical software SigmaStat 3.1 (Systat
Software Inc, San Jose, CA).
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5.0. Results
5.1. Food Intake and Body Weights
No differences were observed in total food intake, weight gain, or final body weight
among the treatment groups (Table 3)

5.2. Bone Morphometry
In the femur, depth measured at diaphysis was smaller (P=0.03) in KO-fed rats compared
to FO-fed rats. There were no significant differences in femoral length, width, or dry weight
among the different treatment groups (Table 4).
In the tibiae, rats fed TO had longer bones (P<0.001) than rats fed CO, FO, KO, or MO.
Rats fed SO and TO had heavier (P<0.001) tibiae dry weight compared to KO or CO-fed rats.
FO (P=0.04) and MO-fed rats (P=0.006) had heavier tibiae dry weight compared to CO-fed rats.
There were no significant differences in depth or width in the tibiae among the different
treatment groups (Table 4).

5.3. Bone Mineralization
In the femur, there were no significant differences in BMA, BMC, BMD, bone ash, Ca,
or P content among the treatment groups (Table 5).
In the tibia, BMA of TO or SO-fed rats was higher compared to rats fed CO (P<0.001),
KO (P=0.01), or MO (P=0.03). Rats fed TO or SO had higher BMC (P<0.001) than CO-fed
rats. BMD in was higher (P=0.006) in TO-fed rats compared to CO-fed rats (Table 5). Ash
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weight was higher (P<0.001) in rats fed TO, SO, MO, or FO compared to rats fed KO or CO.
There was no significant difference in tibia Ca or P content (Table 5).

5.4. Bone Microarchitecture
In the femur, feeding different sources of ω-3 PUFAs resulted in significant differences
in trabecular µCT measurements of BV/TV, TbN, TbSp, and CONN but had no effects on SMI
or TbTh. Rats fed FO or MO had greater BV/TV (P=0.002), TbN (P=0.003), and CONN
(P=0.002) and lower TbSp (P=0.003) than CO-fed rats (Table 6).
In the tibia, feeding different sources of	
  ω-3 PUFAs resulted in significant differences in
trabecular µCT measurements of BV/TV, TbN, ThTh, TbSp, CONN, and SMI. FO-fed rats had
higher (P=0.007) BV/TV than rats fed CO or SO. Rats fed FO or MO had a higher TbN
(P=0.003) than rats fed CO. Rats fed FO had a higher (P=0.04) TbTh than SO-fed rats. Rats fed
FO or MO had higher (P=0.013) CONN compared to rats fed CO. FO, KO, MO, or TO-fed rats
had lower (P<0.001) TbSp compared to rats fed CO (Table 6). FO-fed rats had a lower SMI
compared to CO-fed rats (P=0.04) and SO-fed rats (P=0.02).
In the femur, cortical µCT resulted in no significant differences in cortical area, CtTh,
and porosity among the treatment groups. Cortical femur BV/TV was lower (P=0.02) in SO-fed
rats compared to CO-fed rats. In the cortical tibiae, there were no significant differences in
BV/TV, CtTh, cortical area, and porosity among the treatment groups (Table 7).
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5.5. Bone Biomechanical Strength
There was no significant difference in femur or tibia biomechanical strength measures of
peak force, ultimate stiffness, ultimate bending stress, Young’s Modulus, or bending energy
failure energy (Table 8).

5.6. Mineral Balance
There were no significant differences in baseline Ca intake, urinary Ca excretion, nor Ca
retention. There were no significant differences in final Ca urine, fecal excretion, apparent
absorption or retention (Table 9). Rats fed SO had a higher fecal Ca excretion compared to FO
(P<0.001), KO (P=0.02), or MO (P<0.001). Rats fed TO had a higher fecal Ca excretion
compared to FO (P<0.001), KO (P=0.005), or MO (P<0.001). Rats fed FO and MO had a lower
(P=0.02) fecal Ca excretion compared to CO. Baseline apparent absorption of Ca was higher in
FO compared to CO (P=0.03), SO (P<0.001), or TO (P<0.001). It was also higher in MO
compared to CO (P=0.02), SO (P<0.001), or TO (P<0.001) (Table 9).
At baseline, rats fed KO had a higher (P<0.001) P intake compared to CO, FO, MO, SO,
or TO (Table 10). Rats fed SO also had a higher P intake at baseline compared to CO (P=0.002),
FO (P<0.001), MO (P=0.02), or TO (P=0.02). At final, rats fed KO had a higher (P<0.001) P
intake compared to CO, FO, MO, SO, or TO. Rats fed SO had a higher P intake at final
compared to CO (P=0.006), FO (P=0.001), or MO (P=0.005). Rats fed KO, SO, or TO had a
higher (P<0.001) fecal P excretion at baseline compared to FO or MO. Rats fed KO had a higher
final P fecal excretion than rats fed FO (P<0.001) or MO (P<0.001) or TO (P=0.03) (Table 10).
At baseline, rats fed FO had a higher urinary P excretion compared to MO (P=0.03), SO
(P<0.001), or TO (P<0.001). Rats fed KO had a higher (P<0.001) final P urine excretion than
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rats fed CO, FO, MO, SO, or TO (Table 10). Rats fed FO at baseline had a higher P absorption
rate compared to KO (P=0.049), SO (P=0.03), or TO (P=0.002). Also at baseline, rats fed MO
had a higher (P=0.005) P absorption rat compared to TO. Rat fed FO at final did not have a
significantly different P absorption rate. At baseline, rats fed KO had a higher (P<0.001) P
retention compared to CO, FO, MO, or TO. Also at baseline, rats fed SO had a higher P
retention compared to CO (P=0.005), FO (P<0.001), MO (P=0.048), or TO (P=0.03) (Table 10).
There was no significant difference in P retention at final.

5.7. Biochemical Measurements
There was no significant difference in serum Ca, P, alkaline phosphate, or PYD. Serum
osteocalcin was higher in rats fed FO (P=0.03) compared to rats fed TO or SO. Rats fed SO or
TO had lower serum TBARS than rats fed MO (P=0.004), KO (P=0.005), or CO (P=0.003).
There were no significant differences in total antioxidants (Table 13). Serum TNF-α was below
detectable levels (Table 13). Detection limit of TNF-α was 31.25 pg TNF-α /mL serum.
Relative urinary PGE2 resulted in no difference in FO compared to CO, but was lower in KO,
MO, SO, or TO compared to CO and FO (Figure 5).
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Table 3: Food Intake, Weight Gain, and Final Body Weight of Growing Female Rats Fed Different Sources of Omega-3
Polyunsaturated Fatty Acids3
Treatments
Total Food Intake (g) Weight gain (g)
Final Body Weight (g)
CO
750.1 ± 12.5
75.99 ± 7.42
214.92 ± 6.36
FO
762.9 ± 14.3
103.75 ± 8.11
239.58 ± 8.24
KO
767.5 ± 10.9
98.39 ± 6.12
231.70 ± 6.58
MO
761.2 ± 17.6
107.60 ± 12.53
241.46 ± 14.39
SO
706.8 ± 17.4
85.97 ± 8.41
215.49 ± 10.27
TO
738.3 ± 16.4
106.02 ± 6.66
234.95 ± 8.19
P value
0.06
0.06
0.19

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
are expressed as the mean ± SEM of n=10 rats/group. Abbreviations are CO=corn oil, FO=flaxseed oil, KO=krill oil,
MO=menhaden oil, SO=salmon oil, TO=tuna oil.	
  

3	
  Values
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Table 4: Bone Morphometry of Growing Female Rats Fed Different Sources of Omega-3 Polyunsaturated Fatty Acids4
Treatments
Length (cm)
Depth (mm)
Width (mm)
Dry Weight (g)
Femur
CO
3.16 ± 0.01
4.60 ± 0.14 ab
3.08 ± 0.17
0.47 ± 0.01
FO
3.21 ± 0.03
4.84 ± 0.12 b
3.08 ± 0.10
0.50 ± 0.01
KO
3.13 ± 0.01
4.36 ± 0.17 a
3.24 ± 0.16
0.47 ± 0.01
MO
3.14 ± 0.01
4.73 ± 0.06 ab
2.99 ± 0.04
0.50 ± 0.01
SO
3.13 ± 0.02
4.81 ± 0.08 ab
3.01 ± 0.03
0.48 ± 0.01
TO
3.18 ± 0.03
4.79 ± 0.07 ab
2.98 ± 0.03
0.48 ± 0.01
P value
0.05
0.026
0.53
0.09
Tibia
CO
FO
KO
MO
SO
TO
P value

3.55 ± 0.03 a
3.60 ± 0.03 a
3.51 ± 0.04 a
3.59 ± 0.03 a
3.63 ± 0.03 ab
3.72 ± 0.02 b
<0.001

3.65 ± 0.06
3.83 ± 0.12
3.67 ± 0.08
3.80 ± 0.06
3.92 ± 0.06
3.87 ± 0.05
0.07

2.62 ± 0.06
2.81 ± 0.09
2.83 ± 0.07
2.79 ± 0.08
2.88 ± 0.07
2.79 ± 0.07
0.27

0.30 ± 0.01 a
0.34 ± 0.01 bc
0.32 ± 0.01 ab
0.35 ± 0.01 bc
0.37 ± 0.01 c
0.38 ± 0.01 c
<0.001

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
4	
  Values are expressed as the mean ± SEM of n=10 bone pairs/group. Different letters a, b, c, within the same column indicate
significant differences at P<0.05 by one-way ANOVA followed by Tukey’s test. Abbreviations are CO=corn oil, FO=flaxseed oil,
KO=krill oil, MO=menhaden oil, SO=salmon oil, TO=tuna oil.
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Table 5: Bone Mineralization in Growing Female Rats Fed Different Sources of Omega-3 Polyunsaturated Fatty Acids5
Treatment
BMA (cm2)
BMC (g)
BMD (mg/cm2) Ash Weight (g) Ca (mg/g bone)
P (mg/g bone)
Femur
CO
1.56 ± 0.02
0.33 ± 0.01
0.211 ± 0.003
0.294 ± 0.004
399.2 ± 8.2
187.0 ± 3.5
FO
1.55 ± 0.05
0.35 ± 0.02
0.225 ± 0.003
0.319 ± 0.007
413.9 ± 8.0
193.7 ± 3.0
KO
1.54 ± 0.03
0.34 ± 0.01
0.220 ± 0.003
0.303 ± 0.006
392.7 ± 11.8
183.9 ± 5.2
MO
1.56 ± 0.03
0.34 ± 0.01
0.220 ± 0.003
0.314 ± 0.005
401.7 ± 5.3
188.0 ± 1.8
SO
1.55 ± 0.04
0.33 ± 0.01
0.212 ± 0.004
0.298 ± 0.009
395.6 ± 7.6
185.9 ± 3.3
TO
1.58 ± 0.04
0.35 ± 0.01
0.219 ± 0.003
0.312 ± 0.007
392.6 ± 5.3
183.9 ± 2.1
P value
0.98
0.79
0.08
0.06
0.42
0.31
Tibia
CO
FO
KO
MO
SO
TO
P value

1.12 ± 0.01 a
1.21 ± 0.03 ab
1.17 ± 0.04 a
1.18 ± 0.02 a
1.28 ± 0.04 b
1.32 ± 0.03 b
<0.001

0.19 ± 0.01 a
0.21 ± 0.01 ab
0.20 ± 0.01 ab
0.21 ± 0.01 ab
0.23 ± 0.01 b
0.24 ± 0.01 b
<0.001

0.165 ± 0.002 a
0.177 ± 0.002 ab
0.171 ± 0.003 ab
0.176 ± 0.001 ab
0.176 ± 0.004 ab
0.181 ± 0.003 b
0.009

0.189 ± 0.004 a
0.216 ± 0.005 b
0.202 ± 0.005 a
0.216 ± 0.005 b
0.217 ± 0.007 b
0.231 ± 0.004 b
<0.001

381.6 ± 5.2
386.6 ± 7.0
391.3 ± 9.8
366.0 ± 16.2
406.1 ± 6.8
396.6 ± 4.8
0.05

181.7 ± 2.3
183.3 ± 3.1
186.0 ± 4.4
178.6 ± 5.6
190.0 ± 2.9
187.5 ± 1.9
0.26

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
are expressed as the mean ± SEM of n=7-10 bones/group. Different letters a, b, within the same column indicate significant
differences at P<0.05 by one-way ANOVA followed by Tukey’s test. Abbreviations are BMA=bone mineral area, BMC= bone
mineral content, BMD= bone mineral density, Ca=calcium, P=phosphorus, CO=corn oil, FO=flaxseed oil, KO=krill oil,
MO=menhaden oil, SO=salmon oil, TO=tuna oil.
	
  

5	
  Values
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Table 6: Trabecular Bone Microarchitecture of Growing Female Rats Fed Different Sources of Omega-3 Polyunsaturated
Fatty Acids6
Treatment
BV/TV (%)
TbN (per mm)
TbTh (mm)
TbSp (mm)
CONN (1/mm3)
SMI
Femur
CO
8.0	
  ± 0.7 a
2.31 ± 0.15 a
0.059 ± 0.001
0.46 ± 0.03 b
34.30 ± 4.20 a
2.39 ± 0.06
FO
14.0 ± 1.0 b
3.28 ± 0.22 b
0.063 ± 0.001
0.32 ± 0.02 a
64.03 ± 5.07 b
2.16 ± 0.08
KO
11.0 ± 0.9 ab
2.65 ± 0.23 ab
0.065 ± 0.003
0.41 ± 0.03 ab
44.30 ± 5.51 ab
2.45 ± 0.07
MO
14.0 ± 0.7 b
3.18 ± 0.19 b
0.066 ± 0.002
0.33 ± 0.02 a
60.88 ± 5.63 b
2.19 ± 0.07
SO
11.0 ± 1.5 ab
2.57 ± 0.13 ab
0.063 ± 0.003
0.40 ± 0.02 ab
43.98 ± 7.09 ab
2.38 ± 0.12
TO
11.0 ± 0.8 ab
2.83 ± 0.17 ab
0.061 ± 0.001
0.38 ± 0.03 ab
46.49 ± 4.27 ab
2.43 ± 0.07
P value
0.002
0.003
0.17
0.003
0.002
0.05
Tibia
CO
FO
KO
MO
SO
TO
P value

13.06 ± 1.78 a
23.23 ± 1.93 b
18.68 ± 1.57 ab
21.09 ± 2.29 ab
15.95 ± 1.59 a
18.93 ± 1.42 ab
0.007

2.13 ± 0.29 a
3.41 ± 0.27 b
3.09 ± 0.25 ab
3.53 ± 0.27 b
2.70 ± 0.18 ab
3.12 ± 0.15 ab
0.003

0.076 ± 0.001 ab
0.082 ± 0.002 b
0.080 ± 0.002 ab
0.081 ± 0.002 ab
0.075 ± 0.001 a
0.078 ± 0.001 ab
0.020

0.52 ± 0.07 b
0.31 ± 0.03 a
0.33 ± 0.29 a
0.28 ± 0.02 a
0.39 ± 0.03 ab
0.32 ± 0.02 a
<0.001

35.42 ± 7.88 a
73.50 ± 6.94 b
59.04 ± 5.83 ab
68.45 ± 9.85 b
48.92 ± 6.95 ab
58.91 ± 4.94 ab
0.013

2.32 ± 0.08 b
1.77 ± 0.12 a
2.17 ± 0.08 ab
2.03 ± 0.15 ab
2.31 ± 0.12 b
2.09 ± 0.11 ab
0.021

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
are expressed as the mean ± SEM of n=9-10 bones/group. Different letters a, b, within the same column indicate significant
differences at P<0.05 by one-way ANOVA followed by Tukey’s test. Abbreviations are BV/TV= trabecular bone volume per unit of
total volume, TbN=Trabecular number, TbTh=Trabecular thickness, TbSp=Trabecular space, CONN=Connectivity, SMI=Structure
model index, , CO=corn oil, FO=flaxseed oil, KO=krill oil, MO=menhaden oil, SO=salmon oil, TO=tuna oil.
	
  

6	
  Values
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Table 7: Cortical Bone Microarchitecture of Growing Female Rats Fed Different Sources of Omega-3 Polyunsaturated
Fatty Acids7
Treatment
BV/TV (%)
CtTh (mm)
Cortical Area
Porosity (%)
(mm2)
Femur
CO
96.0 ± 0.1 b
0.548 ± 0.007
4.95 ± 0.07
4.02 ± 0.13
FO
95.1 ± 0.2 ab
0.548 ± 0.009
5.18 ± 0.11
4.86 ± 0.22
KO
95.4 ± 0.1 ab
0.542 ± 0.006
5.10 ± 0.13
4.64 ± 0.13
MO
95.0 ± 0.4 ab
0.538 ± 0.006
5.18 ± 0.12
5.04 ± 0.36
SO
95.0 ± 0.2 a
0.527 ± 0.009
5.24 ± 0.25
4.98 ± 0.22
TO
95.1 ± 0.4 ab
0.546 ± 0.008
5.15 ± 0.15
4.86 ± 0.39
P value
0.024
0.33
0.77
0.07
Tibia
CO
FO
KO
MO
SO
TO
P value

97.8 ± 0.1
97.9 ± 0.1
97.6 ± 0.1
97.6 ± 0.1
97.5 ± 0.2
97.8 ± 0.1
0.57

0.538 ± 0.001
0.569 ± 0.001
0.553 ± 0.005
0.560 ± 0.007
0.556 ± 0.009
0.571 ± 0.008
0.09

3.25 ± 0.04
3.58 ± 0.09
3.64 ± 0.07
3.58 ± 0.05
3.58 ± 0.11
3.58 ± 0.08
0.07

2.18 ± 0.11
2.08 ± 0.13
2.32 ± 0.18
2.36 ± 0.11
2.46 ± 0.26
2.14 ± 0.09
0.51

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
7	
  Values are expressed as the mean ± SEM of n=7-10 bones/group. Different letters a, b, within the same column indicate significant
differences at P<0.05 by one-way ANOVA followed by Tukey’s test. Abbreviations are BV/TV= trabecular bone volume per unit of
total volume, CtTh=Cortical thickness, CO=corn oil, FO=flaxseed oil, KO=krill oil, MO=menhaden oil, SO=salmon oil, TO=tuna oil.
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Table 8: Bone Strength in Growing Female Rats Fed Different Sources of Omega-3 Polyunsaturated Fatty Acids8
Treatment
Peak Force (N)
Ultimate Stiffness
Ultimate Bending
Young’s Modulus
Bending Failure
2
2
(N/S)
Stress (N/mm )
(N/mm )
Energy (N.S)
Femur
CO
119.4 ± 4.5
352.6 ± 34.1
125.3 ± 6.5
3535.0 ± 438.8
21.3 ± 1.5
FO
129.7 ± 5.1
391.9 ± 27.2
126.0 ± 5.6
3587.5 ± 312.9
42.5 ± 17.3
KO
123.4 ± 5.1
395.3 ± 26.3
124.0 ± 4.4
3548.1 ± 242.4
20.5 ± 1.5
MO
130.5 ± 4.3
378.0 ± 31.1
133.6 ± 4.5
3722.3 ± 333.0
26.4 ± 1.4
SO
128.3 ± 6.0
435.9 ± 29.6
127.1 ± 5.0
4054.3 ± 265.0
22.0 ± 1.9
TO
129.3 ± 6.0
424.4 ± 28.2
131.7 ± 5.7
4128.8 ± 293.4
22.2 ± 1.9
P Value
0.61
0.39
0.76
0.64
0.24
Tibia
CO
FO
KO
MO
SO
TO
P Value

81.1 ± 5.6
89.8 ± 6.0
92.2 ± 5.8
93.5 ± 5.0
98.4 ± 4.9
105.7 ± 6.1
0.07

264.5 ± 27.8
312.1 ± 36.7
263.8 ± 29.3
260.6 ± 32.1
351.6 ± 26.8
323.5 ± 19.7
0.13

131.0 ± 8.8
128.1 ± 10.6
130.9 ± 6.5
136.2 ± 11.7
129.3 ± 7.6
148.0 ± 9.3
0.66

4558.5 ± 412.9
4756.9 ± 781.0
3760.0 ± 382.5
3902.2 ± 600.8
4762.0 ± 549.8
4720.4 ± 396.0
0.62

16.7 ± 1.5
16.9 ± 1.1
21.7 ± 2.0
23.1 ± 2.6
18.4 ± 2.0
20.8 ± 1.8
0.09

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
are expressed as the mean ± SEM of n=9-10 bone pairs/group. Abbreviations are CO=corn oil, FO=flaxseed oil, KO=krill oil,
MO=menhaden oil, SO=salmon oil, TO=tuna oil.	
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Table 9: Ca Intake, Excretion, Absorption, and Retention of Growing Female Rats Fed Different Sources of Omega-3
Polyunsaturated Fatty Acids9
Treatment
Ca Intake (mg/d)
Fecal Ca Excretion
Urinary Ca
Ca Absorption* Rate Ca Retention†
(mg/d)
Excretion (mg/d)
(%)
(mg/d)
Baseline
CO
78.479 ± 3.407
20.683 ± 1.969 bc
72.596 ± 3.323 a
69.056 ± 7.221
0.269 ± 0.070
FO
80.006 ± 3.171
12.996 ± 0.945 a
83.620 ± 1.181 b
71.283 ± 3.354
0.339 ± 0.079
KO
80.000 ± 3.566
18.339 ± 1.874 ab
0.236 ± 0.074
76.715 ± 2.525 ab
69.515 ± 5.441
MO
78.876 ± 3.772
12.636 ± 0.766 a
0.179 ± 0.063
83.507 ± 1.436 b
73.966 ± 5.188
SO
82.300 ± 1.075
26.464 ± 2.049 c
0.330 ± 0.065
68.019 ± 2.159 a
59.112 ± 2.183
TO
83.786 ± 1.448
27.502 ± 2.102 c
0.327 ± 0.073
67.207 ± 2.382 a
57.125 ± 1.907
P Value
0.78
<0.001
0.54
<0.001
0.06
Final Week
CO
FO
KO
MO
SO
TO
P Value

86.799 ± 4.403 b
71.883 ± 1.899 ab
82.090 ± 4.064 ab
77.021 ± 4.102 ab
77.855 ± 4.291 ab
70.909 ± 2.917 a
0.034

45.373 ± 6.590
30.018 ± 1.765
47.251 ± 3.682
31.157 ± 3.775
37.903 ± 4.522
35.624 ± 2.947
0.019

0.671 ± 0.298
0.575 ± 0.127
0.507 ± 0.212
0.668 ± 0.209
0.216 ± 0.041
0.458 ± 0.335
0.73

48.589 ± 6.455
58.304 ± 2.206
40.616 ± 5.755
60.208 ± 3.715
50.716 ± 5.774
49.204 ± 4.282
0.08

40.754 ± 5.459
41.291 ± 1.786
34.332 ± 6.023
45.195 ± 2.952
39.735 ± 5.279
34.828 ± 3.805
0.52

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
are expressed as the mean ± SEM of n=10 rats/group
*
Ca absorption rate (%) = (Ca intake – Fecal Ca excretion) / Ca intake x 100; Δ Ca absorption = Final week – Baseline week
†
Ca retention = Total Ca Intake – (Fecal Ca excretion + Urinary Ca excretion); Δ Ca retention = Final week – Baseline week
Abbreviations are Ca=calcium, CO=corn oil, FO=flaxseed oil, KO=krill oil, MO=menhaden oil, SO=salmon oil, TO=tuna oil.
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Table 10: P Intake, Excretion, Absorption, and Retention of Growing Female Rats Fed Different Sources of Omega-3
Polyunsaturated Fatty Acids10
Treatment
P Intake (mg/d)
Fecal P
Urinary P
P Absorption*
P Retention†
Excretion (mg/d) Excretion (mg/d)
Rate (%)
(mg/d)
Baseline
CO
47.354 ± 2.056 a
7.899 ± 0.485 ab 3.854 ± 0.934 ab
82.631 ± 1.680 abc 35.601 ± 2.724 a
FO
45.323 ± 1.796 a
5.315 ± 0.501 a
6.377 ± 1.278 b
88.686 ± 1.239 b
33.631 ± 2.950 a
KO
78.313 ± 3.491 c
8.302 ± 0.905 b
3.466 ± 0.474 ab
82.224 ± 2.253 ac 66.545 ± 3.683 b
MO
47.137 ± 2.254 a
5.494 ± 0.246 a
3.128 ± 0.509 a
88.104 ± 0.814 bc 38.515 ± 2.142 a
SO
59.249 ± 0.774 b
8.968 ± 0.670 b
1.500 ± 0.205 a
81.889 ± 1.258 ac 48.781 ± 0.790 b
TO
49.482 ± 0.855 a
10.198 ± 0.892 b 1.550 ± 0.186 a
79.764 ± 1.617 a
37.734 ± 0.997 a
P Value
<0.001
<0.001
<0.001
<0.001
<0.001
Final Week
CO
FO
KO
MO
SO
TO
P Value

36.506 ± 1.852 a
34.955 ± 0.923 a
62.923 ± 3.115 c
36.272 ± 1.932 a
47.756 ± 2.632 b
39.219 ± 1.613 ab
<0.001

17.738 ± 2.144 ab
12.589 ± 0.723 a
24.218 ± 1.789 b
13.331 ± 1.492 a
18.992 ± 2.448 ab
16.363 ± 1.293 a
<0.001

4.330 ± 1.864 a
7.533 ± 1.735 a
21.316 ± 2.065 b
4.176 ± 1.311 a
2.647 ± 0.323 a
3.197 ± 0.642 a
<0.001

51.616 ± 5.175
63.987 ± 1.964
60.421 ± 3.609
63.482 ± 3.320
59.634 ± 5.007
57.810 ± 3.391
0.26

14.438 ± 3.402
14.833 ± 1.919
17.389 ± 5.049
18.765 ± 2.128
26.117 ± 3.247
19.659 ± 1.736
0.12

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
are expressed as the mean ± SEM of n=10 rats/group
*
P absorption rate (%) = (P intake – Fecal P excretion) / P intake x 100; Δ P absorption = Final week – Baseline week
†
P retention = Total P Intake – (Fecal P excretion + Urinary P excretion); Δ P retention = Final week – Baseline week
Values are expressed as the mean ± SEM of n=10 rats/group. Different letters a, b, within the same column indicate significant
differences at P<0.05 by one-way ANOVA followed by Tukey’s test. Abbreviations are P=phosphorous, CO=corn oil, FO=flaxseed
oil, KO=krill oil, MO=menhaden oil, SO=salmon oil, TO=tuna oil.	
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Table 11: Serum Measurements of Bone Turnover and Oxidative Stress of Growing Female Rats Fed Different Sources of
Omega-3 Polyunsaturated Fatty Acids11
Treatment
Ca (mg/dL) P (mg/dL) ALP (U/L)
PYD
Osteocalcin
TBARS
Total
(nmol/L )
(ng/µL)
(µM MDA) Antioxidants
(mM Trolox)
CO
15.2 ± 1.1
10.7 ± 0.7
261.8 ± 39.5 6.735 ± 0.904 176.0 ± 27.0 ab 6.9 ± 0.4 b
1.5 ± 0.2
FO
14.0 ± 1.0
10.5 ± 0.4
223.5 ± 50.0 6.597 ± 0.497 164.5 ± 23.4 b
5.9 ± 0.2 ab
1.1 ± 0.1
KO
13.0 ± 1.1
10.5 ± 0.7
195.4 ± 24.9 7.146 ± 0.531 132.1 ± 11.0 ab 6.5 ± 0.3 b
1.3 ± 0.1
MO
13.7 ± 0.5
10.6 ± 0.6
163.1 ± 17.0 5.985 ± 0.295 131.2 ± 16.1 ab 6.8 ± 0.3 b
1.5 ± 0.2
SO
13.0 ± 0.5
9.8 ± 0.5
170.3 ± 18.2 7.398 ± 0.454 136.5 ± 8.0 a
5.1 ± 0.3 a
1.1 ± 0.2
TO
12.6 ± 0.3
10.1 ± 0.2
167.0 ± 17.1 7.103 ± 0.514 107.6 ± 15.3 a
5.2 ±0.2 a
1.2 ± 0.2
P Value
0.24
0.83
0.19
0.55
0.015
0.005
0.28

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
11	
  Values are expressed as the mean
± SEM of n=8-10 rats/group. Different letters a, b, within the same column indicate significant
differences at P<0.05 by one-way ANOVA followed by Tukey’s test. Abbreviations are Ca=calcium, P=Phosphorus, ALP=Alkaline
phosphatase, TBARS= Thiobarbituric acid reactive substances, PYD=Pyridinoline, CO=corn oil, FO=flaxseed oil, KO=krill oil,
MO=menhaden oil, SO=salmon oil, TO=tuna oil.
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Figure 5: Relative Percent of Urine Prostaglandin E2 12

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
12
Abbreviations are: PGE2=prostaglandin E2, CO=corn oil, KO=krill oil, MO=menhaden oil, FO=flaxseed oil, TO=tuna oil,
SO=salmon oil	
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6.0. Discussion
This study demonstrated that certain sources of ω-3 PUFAs have a positive effect on the
long bone of growing female rats fed a high (12%) fat diet. The results showed that the different
sources of ω-3 PUFAs had different effects on bone morphometry. TO-fed rats had a greater
tibia longitudinal growth compared to all groups except SO fed rats (P=0.03). In our study, TO
followed by SO were the richest sources of DHA among the different sources of ω-3 PUFA.
Reinwald et al. (2004) reported increased (P=0.03) tibiae length in weanling female and male
Long-Evan rats fed an essential fatty acid deficient diet supplemented with DHA for 8 weeks
compared to those fed an ω-3 PUFA adequate diet. Li et al. (2010) fed Long-Evans pregnant
rats a preformed docosapentaenoic acid (DPA,	
  22:5	
  ω-6) to yield ω-3 deficient pups. The pups
were then fed a diet of DHA, DPA, or DHA plus DPA. The authors found that DHA
accumulated in the osteoblast-rich periosteum of the bone. Therefore, in our study, the
mechanism for greater tibia length in TO-fed rats may be due to DHA activating osteoblasts to
have been shown to promote greater bone growth. Rats fed KO had reduced (P=0.03) femoral
depth than rats fed FO. Additionally, tibia weight was lighter in rats fed KO compared to rats
fed SO (P=0.007) and TO (P=0.002). KO is high in phospholipids, and oxidized phospholipids
promoted osteoclast activity (Tseng et al., 2010), which may lead to the lighter and thinner bones
observed in this study.
In addition to changes in bone morphometry, feeding different sources of ω-3 PUFAs to
female growing rats affected bone mineralization. Tibial BMD was higher (P=0.009) in TO-fed
rats compared to rats fed CO. Tibial BMA (P<0.001) and BMC (P<0.001) were also higher in
rats fed TO as well as SO compared to rats fed CO.
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There was no effect of ω-3 PUFA supplementation on femur mineralization. Sirois et al.
(2003) reported female Sprague-Dawley rats fed either a diet consisting of soybean oil, rich in
ALA, or menhaden oil, rich in DHA, for 5 weeks also had no effect on femoral BMC and BMD. 	
  
In a restricted-feeding (50% calorie reduction in food) rat study (Sun et al., 2004), female Wistar
rats that consumed DHA showed no change in femoral BMD. In our study, changes in bone
mineralization occurred in the tibiae, but not in the femur may be due to the tibiae having a
higher turnover rate than femurs (Wallace, 2007). The tibiae have a higher turnover rate because
the tibiae are subjected to more complex loading state than femurs (Wallace, 2007). In a human
study of adolescent white males (average age 16.7 years), a higher ratio ω-6:ω-3 PUFA intake
showed a negative correlation to spine BMD (r= -0.26, P=0.02); whereas, serum DHA and ω-3
PUFA concentrations were positively correlated to spine (r=0.30, P=0.008) and total body BMD
(r=0.32, P=0.004) (Hogstrom, 2007). The results suggested consumption of ω-3 PUFA,
especially DHA, increased bone mineralization during growth. In our study, TO, the richest
source of DHA, promoted bone mineralization to a greater extent than the other sources of ω-3
PUFA.
The current study also included measurement of cortical and trabecular bone. Cortical
microarchitecture was not affected by feeding different sources of ω-3 PUFAs with the exception
of lower (P=0.06) femur cortical BV/TV in rats fed SO compared to rats fed CO. Reinwald et al.
(2004), reported that femoral cortical bone was not as responsive to ω-3 PUFA repletion in rats
fed an essential fatty acid deficient diet. In contrast, trabecular bone is more metabolically active
and undergoes more rapid remodeling than cortical bone (Watts, 1999). In the current study,
MO and particularly FO appeared to be the sources of ω-3 PUFA that improved bone
microarchitecture quality. Rats fed FO or MO had increased tibia trabecular bone indicated by
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higher BV/TV (P=0.007) and trabecular thickness (P=0.02) than rats fed CO and SO. Rats fed
FO or MO had increased tibia TbN (P=0.003) and CONN (P=0.01) compared to rats fed CO.
FO followed by MO had the highest amount of ALA compared to the other oils. Therefore
improved microarchitecture in the bones of growing female rats may be due to the ALA.
Maximizing bone mineralization and bone matrix should result in stronger bones.
Despite microarchitecture and mineralization differences in rats fed different sources of ω-3
PUFAs in our study, there were no significant differences in biomechanical strength. Similarly,
Kruger et al. (2005) reported that rats fed either corn, evening primrose, or tuna oil for 6 weeks
had no significant differences in bone biomechanical strength. Absence of strength differences
in our study may be due to different effects of different sources of ω-3 PUFAs on bone. TO and
SO increased bone mineralization and FO and MO increased trabecular microarchietecture
quality, yet no group did both. Since both mineralization and microarchitecture is important for
bone strength, oil that only improves one aspect will not improve bone strength. However
maximizing bone mineralization and bone matrix during growth may preserve against future agerelated bone loss leading to risk of osteoporosis (Cashman, 2007).
The study results suggested that different sources of ω-3 PUFAs may act differently on
bone. Of the different sources of ω-3 PUFAs, rats fed TO and SO increased bone mineralization
and rats fed MO and FO increased trabecular microarchitecture quality. Potential mechanisms of
actions of the different sources of ω-3 PUFAs on bone health were investigated.
Indirectly, dietary fats may affect bone by altering Ca balance. Kruger et al. (2005)
reported that young (age 5 weeks) male Sprague-Dawley rats fed 5% tuna oil g/kg diet had
significantly higher Ca absorption and decreased urinary Ca compared to the rats fed evening
primrose oil. The authors suggested that cell membrane saturation reduced Ca absorption. The
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then decreased cell membrane saturation due to ω-3 PUFA consumption resulted in increased Ca
absorption and decreased urinary Ca loss. Our study showed feeding TO had no significant
effect on final Ca absorption or urinary excretion. Compared to the other sources of	
  ω-3 PUFA
Kruger et al. (2005) also suggested that essential fatty acids LA or ALA might affect Ca
retention. Claassen et al., (1995a) fed growing (age 21 days) male Sprague-Dawley rats 3:1
gamma-LA:EPA decreased Ca excretion and had higher (P<0.05) bone Ca content compared to
rats fed 1:3 gamma-LA:EPA. In our study, there was no difference in bone Ca content among
any of the different sources of ω-3 PUFA. A mineral balance change observed was KO-fed rats
had a greater final P urine excretion (P<0.001) compared to the other groups and a greater final P
fecal excretion (P<0.001) compared to rats fed FO, MO, or TO. This may be due to the high P
content associated with the high phospholipid content in KO (Gigliotti et al. 2010). However,
these changes in P balance did not result in higher bone P in rats fed KO.
Another mechanism whereby ω-3 PUFAs may affect bone is by influencing oxidative
stress. Oxidative stress may increase pro-inflammatory cytokines, which lead to an uncoupling
of bone remodeling in favor of bone resorption (McLean et al., 2009). In the current study, rats
fed TO or SO have reduced lipid oxidation indicated by lower (P<0.005) serum TBARS
compared to rats fed CO, KO, or MO. PGE2, a pro-inflammatory eicosanoid, showed lower
relative urinary PGE2 in rats fed SO or TO compared to CO. TNF-α, a pro-inflammatory
cytokine, was below detectable levels in this study. The combination of reduced lipid
peroxidation and pro-inflammation may have contributed to higher bone mineralization in rats
fed TO or SO compared to CO. Rats fed FO showed no differences in serum TBARS compared
to CO, but showed improved tibia trabecular microarchitecture. Bones weaken when osteoclast
remove bone faster than osteoblasts deposit bone (Martini 2006). Claassen (1995b) reported
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lower PYD levels in groups with higher levels of EPA and DHA compared to the control of a
LA:ALA ratio of 3:1. In our study, there was no significant difference in PYD, an indicator of
osteoclast activity, between the groups fed different sources of ω-3 PUFAs. However rats fed
FO showed bone formation indicated by no differences in serum PYD and higher serum
osteocalcin, an indicator of bone formation, compared to rats fed SO and TO. It is important to
note that the bone turnover markers were taken at a single time point; therefore it is more
difficult to make generalizations based on this data.
A potential mechanism whereby ω-3 PUFAs may influence bone formation is by altering
the synthesis of PG. The essential fatty acid linoleic acid (LA, 18:2 ω-6) can be metabolized to
AA and then PGE2. A high concentration of PGE2 inhibits bone formation (Mollard et al.,
2005). FO is high in ALA, an ω-3 PUFA that competes with LA for the delta-6 desaturase. This
makes ALA a competitor to the production of PGE2. 	
  Therefore, consumption of FO, ALA
competes with LA for delta-6 desaturase, potentially resulting in decreased enzymes for
conversion of LA to AA. AA is a substrate for the synthesis of pro-inflammatory eicosanoids.
Therefore, competitive inhibition of ALA with LA may result in reduced inflammation. In the
current study, relative urinary PGE2 was not significantly different between FO and CO.
However, there are various other eicosanoids as well as cytokines involved in the inflammatory
response.
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7.0. Summary and Conclusion
The current study found that the source of ω-3 PUFAs is important to bone metabolism.
Rats fed FO or MO, with the highest ALA content of the sources, ω-3 PUFAs showed improved
bone microarchitecture and increased bone formation; whereas rats fed SO or TO, with the
highest DHA of the sources, ω-3 PUFAs improved bone mineralization associated with a
reduction in lipid oxidation. There was no difference in biomechanical strength in any of the
groups. KO-fed rats did not appear to improve bone health compared to CO control indicated by
no change in P or Ca content in bones and microarchitecture. This may be due to the PUFA in
KO being in a phospholipid rather than TAG form.
The study results suggest that rather than focusing on one source of ω-3 PUFAs, perhaps
a variety of sources of ω-3 PUFAs should be consumed in order to improve bone health during
the bone growth stage.
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